Dr. Azzoli is a medical oncologist who specializes in the treatment of lung cancer, mesothelioma and thymoma (Thoracic Oncologist). He has served as faculty at Memorial Sloan-Kettering Cancer Center in New York, NY, and Massachusetts General Hospital Cancer Center in Boston, MA. In 2018, he became the Director of Thoracic Oncology at the Brown University Health Cancer Institute in Providence, RI. Dr. Azzoli conducts phase 1b-2 clinical trials of new drugs for patients with lung cancer, with special interest in drugs which may overcome de novo and acquired resistance to anti-PD1 immune checkpoint blockade. He is also working to develop blood and tissue tests which may detect T-cell mediated anti-cancer immune activity in his patients.
E-mail: cazzoli@brownhealth.org
| Strandberg J, Louie A, Lee S, Hahn M, Srinivasan P, George A, De La Cruz A, Zhang L, Hernandez Borrero L, Huntington KE, De La Cruz P, Seyhan AA, Koffer PP, Wazer DE, DiPetrillo TA, Graff SL, Azzoli CG, Rounds SI, Klein-Szanto AJ, Tavora F, Yakirevich E, Abbas AE, Zhou L, El-Deiry WS. "TRAIL agonists rescue mice from radiation-induced lung, skin or esophageal injury." Journal of Clinical Investigation, vol. 135, no. 5, 2025. |
| El-Deiry WS, Bresson C, Wunder F, Carneiro BA, Dizon DS, Warner JL, Graff SL, Azzoli CG, Wong ET, Cheng L, Mani SA, Safran HP, Williams C, Meissner T, Solomon B, Rubin E, Porgador A, Berchem G, Saintigny P, Onn A, Bar J, Berger R, Gantenbein M, Chen Z, Souza CP, Reis RMV, Sekacheva M, Cervantes A, Dahut WL, Annunziata CM, Gober K, Musallam KM, Al-Shamsi HO, Abu-Gheida I, Salazar R, Limaye S, Aref AT, Reddel RR, Homsi MUA, Rouf A, Dermime S, Suwaidi JA, Vlad C, Buiga R, Omari AA, Abdel-Razeq H, Oñate-Ocaña LF, Nielsen FC, Graham L, Rueter J, Joshua AM, Girda E, Libutti S, Riedlinger G, Salem ME, Farhangfar CJ, Mesa RA, Faltas BM, Elemento O, Pramesh CS, Sengar M, Aoyama S, Ikeda S, Berindan-Neagoe I, Gaddipati H, Kulkarni M, Auzias E, Gerogianni M, Wolikow N, Istolainen S, Schlafrig P, Frankel NZ, Ferraro AR, Palma J, Gimenez AP, Hernando-Calvo A, Felip E, Tsimberidou AM, Herbst RS, Tabernero J, Schilsky RL, Liu J, Lussier Y, Raynaud J, Batist G, Magidi S, Kurzrock R. "Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients." Oncotarget, vol. 16, 2025, pp. 140-162. |
| Kamle S, Ma B, Schor G, Bailey M, Pham B, Cho I, Khan H, Azzoli C, Hofstetter M, Sadanaga T, Herbst R, Politi K, Lee CG, Elias JA. "Chitinase 3-like-1 (CHI3L1) in the pathogenesis of epidermal growth factor receptor mutant non-small cell lung cancer." Translational Oncology, vol. 49, 2024, pp. 102108. |
| Azzoli C, Huynh L, Yi D, Duh MS, Cai B. "Authors' Response to "Letter to the Editor" Submitted by S. Wang and W. Liu (re: "Retrospective Study to Examine Prognostic Value of C-Reactive Protein in Patients With Surgically Resectable Non-Small-Cell Lung Cancer"." Clinical lung cancer, vol. 24, no. 6, 2023, pp. e197. |
| Liguori NR, Sanchez Sevilla Uruchurtu A, Zhang L, Abbas AE, Lee YS, Zhou L, Azzoli CG, El-Deiry WS. "Preclinical studies with ONC201/TIC10 and lurbinectedin as a novel combination therapy in small cell lung cancer (SCLC)." American Journal of Cancer Research, vol. 12, no. 2, 2022, pp. 729-743. |
| Huang B, Sollee J, Luo YH, Reddy A, Zhong Z, Wu J, Mammarappallil J, Healey T, Cheng G, Azzoli C, Korogodsky D, Zhang P, Feng X, Li J, Yang L, Jiao Z, Bai HX. "Prediction of lung malignancy progression and survival with machine learning based on pre-treatment FDG-PET/CT." EBioMedicine, vol. 82, 2022, pp. 104127. |
| Lin JJ, Muzikansky A, Kennedy E, Kuberski H, Stober LL, Wanat AC, Azzoli CG, Lennes I, Sequist LV, Dagogo-Jack I, Shaw AT, Gainor JF. "Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study." ESMO open, vol. 7, no. 1, 2022, pp. 100342. |
| Hart JL, Canepa M, Agarwal S, Lu S, Azzoli C, Garcia-Moliner M. "The effect that pathologic and radiologic interpretation of invasive and non-invasive areas in lung adenocarcinoma has on T-stage and treatment." Annals of diagnostic pathology, vol. 54, 2021, pp. 151799. |
| Hung YP, Chen AL, Taylor MS, Huynh TG, Kem M, Selig MK, Nielsen GP, Lennerz JK, Azzoli CG, Dagogo-Jack I, Kradin RL, Mino-Kenudson M. "Thoracic nuclear protein in testis (NUT) carcinoma: expanded pathological spectrum with expression of thyroid transcription factor-1 and neuroendocrine markers." Histopathology, vol. 78, no. 6, 2021, pp. 896-904. |
| Ng T, Azzoli CG. "Commentary: Chemotherapy for stage IB large cell neuroendocrine carcinomas of lung: Convention becomes conviction." The Journal of Thoracic and Cardiovascular Surgery, vol. 159, no. 5, 2020, pp. 2055-2056. |
| Del Prete C, Azzoli CG. "Non-Small Cell Lung Cancer in the Era of Personalized Medicine: Molecular Tests that Matter." Rhode Island medical journal (2013), vol. 103, no. 3, 2020, pp. 28-32. |
| Chaudhary SP, Kwak EL, Hwang KL, Lennerz JK, Corcoran RB, Heist RS, Russo AL, Parikh A, Borger DR, Blaszkowsky LS, Faris JE, Murphy JE, Azzoli CG, Roeland EJ, Goyal L, Allen J, Mullen JT, Ryan DP, Iafrate AJ, Klempner SJ, Clark JW, Hong TS. "Revisiting MET: Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic, MET-Amplified Esophagogastric Cancers." The oncologist, vol. 25, no. 11, 2020, pp. e1691-e1700. |
| Cleary JM, Horick NK, McCleary NJ, Abrams TA, Yurgelun MB, Azzoli CG, Rubinson DA, Brooks GA, Chan JA, Blaszkowsky LS, Clark JW, Goyal L, Meyerhardt JA, Ng K, Schrag D, Savarese DMF, Graham C, Fitzpatrick B, Gibb KA, Boucher Y, Duda DG, Jain RK, Fuchs CS, Enzinger PC. "FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial." Cancer, vol. 125, no. 13, 2019, pp. 2213-2221. |
| Canepa M, Patel NR, Griffith RC, Ng TT, Azzoli CG. "KRAS Mutation for Staging Resected Non-Small Cell Lung Cancer." Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, vol. 14, no. 7, 2019, pp. e153-e155. |
| Pennell NA, Neal JW, Chaft JE, Azzoli CG, Jänne PA, Govindan R, Evans TL, Costa DB, Wakelee HA, Heist RS, Shapiro MA, Muzikansky A, Murthy S, Lanuti M, Rusch VW, Kris MG, Sequist LV. "SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer." Journal of Clinical Oncology, vol. 37, no. 2, 2019, pp. 97-104. |
| Piotrowska Z, Costa DB, Oxnard GR, Huberman M, Gainor JF, Lennes IT, Muzikansky A, Shaw AT, Azzoli CG, Heist RS, Sequist LV. "Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions." Annals of Oncology, vol. 29, no. 10, 2018, pp. 2092-2097. |
| Dagogo-Jack I, Brannon AR, Ferris LA, Campbell CD, Lin JJ, Schultz KR, Ackil J, Stevens S, Dardaei L, Yoda S, Hubbeling H, Digumarthy SR, Riester M, Hata AN, Sequist LV, Lennes IT, Iafrate AJ, Heist RS, Azzoli CG, Farago AF, Engelman JA, Lennerz JK, Benes CH, Leary RJ, Shaw AT, Gainor JF. "Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA." JCO precision oncology, vol. 2018, 2018. |
| Kris MG, Gaspar LE, Chaft JE, Kennedy EB, Azzoli CG, Ellis PM, Lin SH, Pass HI, Seth R, Shepherd FA, Spigel DR, Strawn JR, Ung YC, Weyant M. "Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update." Journal of Clinical Oncology, vol. 35, no. 25, 2017, pp. 2960-2974. |
| Farago AF, Azzoli CG. "Beyond <i>ALK</i> and <i>ROS1: RET, NTRK, EGFR</i> and <i>BRAF</i> gene rearrangements in non-small cell lung cancer." Translational lung cancer research, vol. 6, no. 5, 2017, pp. 550-559. |
| Li BT, Drilon A, Johnson ML, Hsu M, Sima CS, McGinn C, Sugita H, Kris MG, Azzoli CG. "A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers." Annals of Oncology, vol. 27, no. 1, 2016, pp. 154-9. |
| Chaft JE, Dunphy M, Naidoo J, Travis WD, Hellmann M, Woo K, Downey R, Rusch V, Ginsberg MS, Azzoli CG, Kris MG. "Adaptive Neoadjuvant Chemotherapy Guided by (18)F-FDG PET in Resectable Non-Small Cell Lung Cancers: The NEOSCAN Trial." Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, vol. 11, no. 4, 2016, pp. 537-44. |
| Klein KA, Azzoli CG, Rifkin LM. "Bilateral acute simultaneous onset anterior uveitis presumed secondary to erlotinib: A report of two cases." American Journal of Ophthalmology Case Reports, vol. 6, 2016, pp. 21-23. |
| Gainor JF, Shaw AT, Sequist LV, Fu X, Azzoli CG, Piotrowska Z, Huynh TG, Zhao L, Fulton L, Schultz KR, Howe E, Farago AF, Sullivan RJ, Stone JR, Digumarthy S, Moran T, Hata AN, Yagi Y, Yeap BY, Engelman JA, Mino-Kenudson M. "EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis." Clin Cancer Res , vol. 22, no. 18, 2016, pp. 4585-93. |
| Bezjak A, Temin S, Azzoli CG. "Reply to B. Jeremic et al." Journal of Clinical Oncology, vol. 34, no. 2, 2016, pp. 197-8. |
| Li BT, Lou E, Hsu M, Yu HA, Naidoo J, Zauderer MG, Sima C, Johnson ML, Daras M, DeAngelis LM, Fleisher M, Kris MG, Azzoli CG. "Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers." PLoS ONE, vol. 11, no. 1, 2016, pp. e0146063. |
| Azzoli CG. "Practical Value of Molecular Pathology in Stage I-III Lung Cancer: Implications for the Clinical Surgeon." Annals of Surgical Oncology, vol. 22, no. 11, 2015, pp. 3459-65. |
| Masters GA, Temin S, Azzoli CG, Giaccone G, Baker S Jr, Brahmer JR, Ellis PM, Gajra A, Rackear N, Schiller JH, Smith TJ, Strawn JR, Trent D, Johnson DH, American Society of Clinical Oncology Clinical Practice. "Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update." Journal of Clinical Oncology, vol. 33, no. 30, 2015, pp. 3488-515. |
| Drilon A, Sugita H, Sima CS, Zauderer M, Rudin CM, Kris MG, Rusch VW, Azzoli CG. "A prospective study of tumor suppressor gene methylation as a prognostic biomarker in surgically resected stage I to IIIA non-small-cell lung cancers." Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, vol. 9, no. 9, 2014, pp. 1272-7. |
| Azzoli CG, Engelman J, Fidias P, Gainor JF, Heist RS, Lamont EB, Lennes IT, Rosovsky RP, Sequist LV, Shaw AT, Temel JS. "Genotyping lung cancer is an investment in the future." Journal of Clinical Oncology, vol. 32, no. 31, 2014, pp. 3576-7. |
| Chaft JE, Litvak A, Arcila ME, Patel P, D'Angelo SP, Krug LM, Rusch V, Mattson A, Coeshott C, Park B, Apelian DM, Kris MG, Azzoli CG. "Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation." Clinical lung cancer, vol. 15, no. 6, 2014, pp. 405-10. |
| Lou E, Johnson M, Sima C, Gonzalez-Espinoza R, Fleisher M, Kris MG, Azzoli CG. "Serum biomarkers for assessing histology and outcomes in patients with metastatic lung cancer." Cancer biomarkers : section A of Disease markers, vol. 14, no. 4, 2014, pp. 207-14. |
| Heist R, Azzoli CG. "Adjuvant therapy for a 3.9-cm adenocarcinoma of the lung." The oncologist, vol. 18, no. 12, 2013, pp. 1258-61. |
| Willers H, Azzoli CG, Santivasi WL, Xia F. "Basic mechanisms of therapeutic resistance to radiation and chemotherapy in lung cancer." Cancer journal (Sudbury, Mass.), vol. 19, no. 3, 2013, pp. 200-7. |
| Mosher CE, Champion VL, Azzoli CG, Hanna N, Jalal SI, Fakiris AJ, Birdas TJ, Okereke IC, Kesler KA, Einhorn LH, Monahan PO, Ostroff JS. "Economic and social changes among distressed family caregivers of lung cancer patients." Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, vol. 21, no. 3, 2013, pp. 819-26. |
| Yu HA, Sima CS, Huang J, Solomon SB, Rimner A, Paik P, Pietanza MC, Azzoli CG, Rizvi NA, Krug LM, Miller VA, Kris MG, Riely GJ. "Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors." Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, vol. 8, no. 3, 2013, pp. 346-51. |
| Chaft JE, Rekhtman N, Sima CS, Rusch V, Kris MG, Zakowski M, Azzoli CG. "Phase II study of docetaxel and vinorelbine as adjuvant chemotherapy for resected non-small cell lung cancers." Cancer chemotherapy and pharmacology, vol. 72, no. 4, 2013, pp. 931-4. |
| Hellmann MD, Chaft JE, Rusch V, Ginsberg MS, Finley DJ, Kris MG, Price KA, Azzoli CG, Fury MG, Riely GJ, Krug LM, Downey RJ, Bains MS, Sima CS, Rizk N, Travis WD, Rizvi NA, Paik PK. "Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab." Cancer chemotherapy and pharmacology, vol. 72, no. 2, 2013, pp. 453-61. |
| Azzoli CG, Temin S, Giaccone G. "2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer." Journal of Oncology Practice, vol. 8, no. 1, 2012, pp. 63-6. |
| Bach PB, Mirkin JN, Oliver TK, Azzoli CG, Berry DA, Brawley OW, Byers T, Colditz GA, Gould MK, Jett JR, Sabichi AL, Smith-Bindman R, Wood DE, Qaseem A, Detterbeck FC. "Benefits and harms of CT screening for lung cancer: a systematic review." JAMA, vol. 307, no. 22, 2012, pp. 2418-29. |
| Chaft JE, Sima CS, Ginsberg MS, Huang J, Kris MG, Travis WD, Azzoli CG. "Clinical outcomes with perioperative chemotherapy in sarcomatoid carcinomas of the lung." Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, vol. 7, no. 9, 2012, pp. 1400-5. |
| D'Angelo SP, Janjigian YY, Ahye N, Riely GJ, Chaft JE, Sima CS, Shen R, Zheng J, Dycoco J, Kris MG, Zakowski MF, Ladanyi M, Rusch V, Azzoli CG. "Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib." Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, vol. 7, no. 12, 2012, pp. 1815-1822. |
| Pietanza MC, Gadgeel SM, Dowlati A, Lynch TJ, Salgia R, Rowland KM Jr, Wertheim MS, Price KA, Riely GJ, Azzoli CG, Miller VA, Krug LM, Kris MG, Beumer JH, Tonda M, Mitchell B, Rizvi NA. "Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer." Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, vol. 7, no. 5, 2012, pp. 856-65. |
| Pietanza MC, Kadota K, Huberman K, Sima CS, Fiore JJ, Sumner DK, Travis WD, Heguy A, Ginsberg MS, Holodny AI, Chan TA, Rizvi NA, Azzoli CG, Riely GJ, Kris MG, Krug LM. "Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker." Clin Cancer Res , vol. 18, no. 4, 2012, pp. 1138-45. |
| Kelly K, Azzoli CG, Zatloukal P, Albert I, Jiang PY, Bodkin D, Pereira JR, Juhász E, Iannotti NO, Weems G, Koutsoukos T, Patel JD. "Randomized phase 2b study of pralatrexate versus erlotinib in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) after failure of prior platinum-based therapy." Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, vol. 7, no. 6, 2012, pp. 1041-8. |
| Schoellnast H, Deodhar A, Hsu M, Moskowitz C, Nehmeh SA, Thornton RH, Sofocleous CT, Alago W Jr, Downey RJ, Azzoli CG, Rosenzweig KE, Solomon SB. "Recurrent non-small cell lung cancer: evaluation of CT-guided radiofrequency ablation as salvage therapy." Acta radiologica (Stockholm, Sweden : 1987), vol. 53, no. 8, 2012, pp. 893-9. |
| Azzoli CG, Temin S, Aliff T, Baker S Jr, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pao W, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D, Giaccone G, American Society of Clinical Oncology. "2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer." Journal of Clinical Oncology, vol. 29, no. 28, 2011, pp. 3825-31. |
| D'Angelo SP, Kris MG, Pietanza MC, Rizvi NA, Azzoli CG. "A case series of dose-limiting peripheral edema observed in patients treated with pemetrexed." Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, vol. 6, no. 3, 2011, pp. 624-6. |
| Paik PK, James LP, Riely GJ, Azzoli CG, Miller VA, Ng KK, Sima CS, Heelan RT, Kris MG, Moore E, Rizvi NA. "A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusion." Cancer chemotherapy and pharmacology, vol. 68, no. 5, 2011, pp. 1331-7. |
| Riely GJ, Johnson ML, Medina C, Rizvi NA, Miller VA, Kris MG, Pietanza MC, Azzoli CG, Krug LM, Pao W, Ginsberg MS. "A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations." Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, vol. 6, no. 8, 2011, pp. 1435-7. |
| Hainsworth JD, Fang L, Huang JE, Karlin D, Russell K, Faoro L, Azzoli C. "BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer." Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, vol. 6, no. 1, 2011, pp. 109-14. |
| Brevet M, Johnson ML, Azzoli CG, Ladanyi M. "Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors." Lung Cancer, vol. 73, no. 1, 2011, pp. 96-102. |
| Janjigian YY, Park BJ, Zakowski MF, Ladanyi M, Pao W, D'Angelo SP, Kris MG, Shen R, Zheng J, Azzoli CG. "Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations." Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, vol. 6, no. 3, 2011, pp. 569-75. |
| Oxnard GR, Janjigian YY, Arcila ME, Sima CS, Kass SL, Riely GJ, Pao W, Kris MG, Ladanyi M, Azzoli CG, Miller VA. "Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib." Clin Cancer Res , vol. 17, no. 19, 2011, pp. 6322-8. |
| Rizvi NA, Rusch V, Pao W, Chaft JE, Ladanyi M, Miller VA, Krug LM, Azzoli CG, Bains M, Downey R, Flores R, Park B, Singh B, Zakowski M, Heelan RT, Shen R, Kris MG. "Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene." Clin Cancer Res , vol. 17, no. 10, 2011, pp. 3500-6. |
| Azzoli CG, Patel JD, Krug LM, Miller V, James L, Kris MG, Ginsberg M, Subzwari S, Tyson L, Dunne M, May J, Huntington M, Saunders M, Sirotnak FM. "Pralatrexate with vitamin supplementation in patients with previously treated, advanced non-small cell lung cancer: safety and efficacy in a phase 1 trial." Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, vol. 6, no. 11, 2011, pp. 1915-22. |
| Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D, Giaccone G. "[American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer]." Zhongguo fei ai za zhi = Chinese journal of lung cancer, vol. 13, no. 3, 2010, pp. 171-89. |
| Sica G, Yoshizawa A, Sima CS, Azzoli CG, Downey RJ, Rusch VW, Travis WD, Moreira AL. "A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors." The American Journal of Surgical Pathology, vol. 34, no. 8, 2010, pp. 1155-62. |
| Janjigian YY, Lee W, Kris MG, Miller VA, Krug LM, Azzoli CG, Senturk E, Calcutt MW, Rizvi NA. "A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors." Cancer chemotherapy and pharmacology, vol. 65, no. 5, 2010, pp. 833-8. |
| Azzoli CG, Giaccone G, Temin S. "American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer." Journal of Oncology Practice, vol. 6, no. 1, 2010, pp. 39-43. |
| De Braganca KC, Janjigian YY, Azzoli CG, Kris MG, Pietanza MC, Nolan CP, Omuro AM, Holodny AI, Lassman AB. "Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer." J Neurooncol, vol. 100, no. 3, 2010, pp. 443-7. |
| Price KA, Azzoli CG, Krug LM, Pietanza MC, Rizvi NA, Pao W, Kris MG, Riely GJ, Heelan RT, Arcila ME, Miller VA. "Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer." Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, vol. 5, no. 10, 2010, pp. 1623-9. |
| Girard N, Deshpande C, Azzoli CG, Rusch VW, Travis WD, Ladanyi M, Pao W. "Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines." Chest, vol. 137, no. 1, 2010, pp. 46-52. |
| Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D, Giaccone G, American Society of Clinical Oncology. "American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer." Journal of Clinical Oncology, vol. 27, no. 36, 2009, pp. 6251-66. |
| Price KA, Azzoli CG, Gaspar LE. "Chemoradiation for unresectable stage III non-small cell lung cancer." Seminars in Thoracic and Cardiovascular Surgery, vol. 20, no. 3, 2008, pp. 204-9. |
| Azzoli CG, Park BJ, Pao W, Zakowski M, Kris MG. "Molecularly tailored adjuvant chemotherapy for resected non-small cell lung cancer: a time for excitement and equipoise." Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, vol. 3, no. 1, 2008, pp. 84-93. |
| Rizvi NA, Riely GJ, Azzoli CG, Miller VA, Ng KK, Fiore J, Chia G, Brower M, Heelan R, Hawkins MJ, Kris MG. "Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer." Journal of Clinical Oncology, vol. 26, no. 4, 2008, pp. 639-43. |
| Marks JL, Broderick S, Zhou Q, Chitale D, Li AR, Zakowski MF, Kris MG, Rusch VW, Azzoli CG, Seshan VE, Ladanyi M, Pao W. "Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma." Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, vol. 3, no. 2, 2008, pp. 111-6. |
| Rusch VW, Azzoli CG, Rosenzweig KE. "Therapeutic options for the treatment of advanced lung cancer: introduction." Seminars in Thoracic and Cardiovascular Surgery, vol. 20, no. 3, 2008, pp. 183. |
| Azzoli CG, Krug LM, Gomez J, Miller VA, Kris MG, Ginsberg MS, Henry R, Jones J, Tyson L, Dunne M, Pizzo B, Farmer A, Venkatraman E, Steffen R, Sirotnak FM. "A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors." Clin Cancer Res , vol. 13, no. 9, 2007, pp. 2692-8. |
| Fury MG, Solit DB, Su YB, Rosen N, Sirotnak FM, Smith RP, Azzoli CG, Gomez JE, Miller VA, Kris MG, Pizzo BA, Henry R, Pfister DG, Rizvi NA. "A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors." Cancer chemotherapy and pharmacology, vol. 59, no. 4, 2007, pp. 467-75. |
| Azzoli CG, Krug LM, Miller VA, Rizvi NA, Kris MG, Dunne M, Farmer A, Pizzo B, Tyson L, Seeger T, Coleman B, Moore E, Lastinger L, Venkatraman E, Rudin CM. "A phase II tolerability study of cisplatin plus docetaxel as adjuvant chemotherapy for resected non-small cell lung cancer." Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, vol. 2, no. 7, 2007, pp. 638-44. |
| Pisters KM, Evans WK, Azzoli CG, Kris MG, Smith CA, Desch CE, Somerfield MR, Brouwers MC, Darling G, Ellis PM, Gaspar LE, Pass HI, Spigel DR, Strawn JR, Ung YC, Shepherd FA, Cancer Care Ontario, American Society of Clinical Oncology. "Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline." Journal of Clinical Oncology, vol. 25, no. 34, 2007, pp. 5506-18. |
| Azzoli CG, Kris MG, Pfister DG. "Cisplatin versus carboplatin for patients with metastatic non-small-cell lung cancer--an old rivalry renewed." JNCI Journal of the National Cancer Institute, vol. 99, no. 11, 2007, pp. 828-9. |
| Milton DT, Riely GJ, Azzoli CG, Gomez JE, Heelan RT, Kris MG, Krug LM, Pao W, Pizzo B, Rizvi NA, Miller VA. "Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer." Cancer, vol. 110, no. 3, 2007, pp. 599-605. |
| Liu V, White DA, Zakowski MF, Travis W, Kris MG, Ginsberg MS, Miller VA, Azzoli CG. "Pulmonary toxicity associated with erlotinib." Chest, vol. 132, no. 3, 2007, pp. 1042-4. |
| Fury MG, Krug LM, Azzoli CG, Sharma S, Kemeny N, Wu N, Kris MG, Rizvi NA. "A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors." Cancer chemotherapy and pharmacology, vol. 57, no. 5, 2006, pp. 671-7. |
| Milton DT, Azzoli CG, Heelan RT, Venkatraman E, Gomez JE, Kris MG, Krug LM, Pao W, Rizvi NA, Dunne M, Miller VA. "A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer." Cancer, vol. 107, no. 5, 2006, pp. 1034-41. |
| Azzoli CG. "Adjuvant chemotherapy for resected non-small-cell lung cancer--ANITA takes the stage." The Lancet Oncology, vol. 7, no. 9, 2006, pp. 701-3. |
| Krug LM, Crapanzano JP, Azzoli CG, Miller VA, Rizvi N, Gomez J, Kris MG, Pizzo B, Tyson L, Dunne M, Heelan RT. "Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial." Cancer, vol. 103, no. 10, 2005, pp. 2128-31. |
| Krug LM, Miller VA, Patel J, Crapanzano J, Azzoli CG, Gomez J, Kris MG, Heelan RT, Pizzo B, Tyson L, Sheehan C, Ross JS, Venkatraman E. "Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma." Cancer, vol. 104, no. 10, 2005, pp. 2149-55. |
| Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, Olak J, Stover D, Strawn JR, Turrisi AT, Somerfield MR, American Society of Clinical Oncology. "American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003." Journal of Clinical Oncology, vol. 22, no. 2, 2004, pp. 330-53. |
| Krug LM, Azzoli CG, Kris MG, Miller VA, Khokhar NZ, Tong W, Ginsberg MS, Venkatraman E, Tyson L, Pizzo B, Baez V, Ng KK, Sirotnak FM. "10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer." Clin Cancer Res , vol. 9, no. 6, 2003, pp. 2072-8. |
| Azzoli CG, Miller VA, Ng KK, Krug LM, Spriggs DR, Tong WP, Riedel ER, Kris MG. "A phase I trial of perillyl alcohol in patients with advanced solid tumors." Cancer chemotherapy and pharmacology, vol. 51, no. 6, 2003, pp. 493-8. |
| Patel JD, Krug LM, Azzoli CG, Gomez J, Kris MG, Miller VA. "Targeting lethal minimal residual disease in small cell lung cancer." Seminars in oncology, vol. 30, no. 1, 2003, pp. 79-85. |
| Azzoli CG, Sagar M, Wu A, Lowry D, Hennings H, Morgan DL, Weinberg WC. "Cooperation of p53 loss of function and v-Ha-ras in transformation of mouse keratinocyte cell lines." Molecular carcinogenesis, vol. 21, no. 1, 1998, pp. 50-61. |
| Weinberg WC, Azzoli CG, Chapman K, Levine AJ, Yuspa SH. "p53-mediated transcriptional activity increases in differentiating epidermal keratinocytes in association with decreased p53 protein." Oncogene, vol. 10, no. 12, 1995, pp. 2271-9. |
| Weinberg WC, Azzoli CG, Kadiwar N, Yuspa SH. "p53 gene dosage modifies growth and malignant progression of keratinocytes expressing the v-rasHa oncogene." Cancer Research, vol. 54, no. 21, 1994, pp. 5584-92. |
| Ball DW, Azzoli CG, Baylin SB, Chi D, Dou S, Donis-Keller H, Cumaraswamy A, Borges M, Nelkin BD. "Identification of a human achaete-scute homolog highly expressed in neuroendocrine tumors." Proceedings of the National Academy of Sciences, vol. 90, no. 12, 1993, pp. 5648-52. |
| Year | Degree | Institution |
|---|---|---|
| 1996 | MD | Johns Hopkins University |
| 1991 | BA | Harvard University |
| Name | Title |
|---|---|
| Dubielecka-Szczerba, Patrycja | Associate Professor of Medicine |
| El-Deiry, Wafik | Mencoff Family University Professor of Medical Science, Professor of Pathology and Laboratory Medicine |
| Elias, Jack | Warren Alpert Foundation Professor of Translational Science, Professor of Molecular Biology, Cell Biology and Biochemistry, Professor of Medicine |
Brown University Health Cancer Institute
Rhode Island Hospital
The Miriam Hospital
